SYK vs VCEL
SYK: A diversified global MedTech leader providing surgical instruments, robotics, and advanced clinical technologies to enhance patient recovery and healthcare outcomes. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | SYK | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $325.70 | $45.32 | |
| Market cap as of 2026-08-03 | $124.9B | $2.3B | |
| P/E as of 2026-08-03 | 37.73 | 109.36 | SYK lower |
| PEG as of 2026-08-03 | 3.68 | 0.38 | VCEL lower |
| Net margin as of 2026-08-03 | +13.2% | +7.3% | SYK higher |
| Gross margin as of 2026-08-03 | +64.2% | +74.8% | VCEL higher |
| Operating margin as of 2026-08-03 | +19.7% | +5.4% | SYK higher |
| ROE as of 2026-08-03 | +15.1% | +6.4% | SYK higher |
| ROA as of 2026-08-03 | +7.1% | +4.6% | SYK higher |
| Debt / equity as of 2026-08-03 | 0.64 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.8% | +22.4% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +18.9% | VCEL higher |
| Dividend yield as of 2026-08-03 | +1.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.56 | 1.07 | |
| 1-year return as of 2026-07-31 close | -17.1% | +13.0% | VCEL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.